The First Nasal Treatment for Anaphylaxis: FDA APPROVED!

Mohamad-Ali Salloum, PharmD • August 17, 2024

Share

  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button
  • Slide title

    Write your caption here
    Button

Anaphylaxis is a severe, life-threatening allergic reaction that can occur rapidly, requiring immediate medical intervention. Traditionally, epinephrine autoinjectors have been the standard of care for such emergencies. However, the recent approval by the U.S. Food and Drug Administration (FDA) of a novel nasal spray, named neffy, marks a significant milestone in the management of anaphylactic reactions

What is Neffy?


Neffy (epinephrine nasal spray) is the first of its kind for the emergency treatment of allergic reactions (Type I), including anaphylaxis, in adult and pediatric patients who weigh at least 30 kilograms (approximately 66 pounds). This approval is particularly noteworthy as it introduces the first non-injectable form of epinephrine, potentially reducing barriers to rapid treatment due to needle phobia

Why Neffy was approved?


The approval of Neffy was based on four studies involving 175 healthy adults, which demonstrated that the epinephrine concentrations in the blood following administration of Neffy were comparable to those achieved with approved epinephrine injection products. Additionally, Neffy showed similar increases in blood pressure and heart rate, which are critical effects of epinephrine in treating anaphylaxis.

How is it Administered?


Neffy is administered as a single dose nasal spray into one nostril and may be given a second dose if symptoms do not improve or worsen. It is important to note that certain nasal conditions, such as nasal polyps or a history of nasal surgery, may affect the absorption of Neffy. In such cases, patients are advised to consult with healthcare professionals regarding the use of injectable epinephrine products

Conclusion:


The introduction of neffy is a welcome addition to the arsenal of anaphylaxis treatments, offering a needle-free alternative that may encourage more timely administration of life-saving epinephrine. As with any new medical product, ongoing monitoring and real-world data will be essential to assess the long-term efficacy and safety of this innovative treatment option.


References :


-FDA Approves First Nasal Spray for Treatment of Anaphylaxis.


Link: https://www.fda.gov/news-events/press-announcements/fda-approves-first-nasal-spray-treatment-anaphylaxis


List of Services

    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button
    • Slide title

      Write your caption here
      Button

    ABOUT THE AUTHOR

    Mohamad-Ali Salloum, PharmD

    Mohamad Ali Salloum LinkedIn Profile

    Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.

    Share

    Recent articles:

    By Mohamad-Ali Salloum, PharmD April 29, 2026
    References: Zaniletti I, Larson DR, Lewallen DG, Berry DJ, Maradit Kremers H. How to Distinguish Correlation from Causation in Orthopaedic Research. J Arthroplasty. 2022;38(4):634‑637. [pmc.ncbi.nlm.nih.gov] Association of Health Care Journalists. Correlation vs. Causation. [healthjournalism.org] Rush J, Ajami M, Look K, Margolis A. Statistics Review Part 10: Causality and Confounding. J Pharm Soc Wis. [jpswi.org] Biostat Prime. Correlation vs Causation: Meaning, Differences & Examples. [biostatprime.com] Koopmans E, Schiller C. Understanding Causation in Healthcare: An Introduction to Critical Realism. Qual Health Res. 2022;32(8–9):1207–1214. [pmc.ncbi.nlm.nih.gov] 
    By Mohamad-Ali Salloum, PharmD April 27, 2026
    References: Very Big Brain. Somatic Memories: How Physical Sensations Trigger Past Memories and Emotions . 2023 Nov 26. [verybigbrain.com] Misattribution of arousal. Wikipedia . 2026. [en.wikipedia.org] Zimbardo P. The Misattribution of Arousal Study (Dutton & Aron) . 2026. [zimbardo.com] Higgins L. Why You Feel Anxious After Drinking Coffee . TIME. 2025 Nov 11. [time.com] Double KS. Metacognitive ability is associated with reduced emotion suppression . Scientific Reports. 2026 Jan 28. [nature.com] Merkebu J et al. What is metacognitive reflection? Front Educ. 2023 Apr 5. [researchgate.net] Meyers S et al. Cognitive Reappraisal is More Effective for Regulating Emotions than Moods . Affective Science. 2025 Jun 6. [link.springer.com] 
    By Mohamad-Ali Salloum, PharmD April 25, 2026
    Are they the same?
    By Mohamad-Ali Salloum, PharmD April 23, 2026
    A Practical Guide for the Public.
    By Mohamad-Ali Salloum, PharmD April 21, 2026
    Did you know that your emotions are just suggestions?
    By Mohamad-Ali Salloum, PharmD April 19, 2026
    Short-form videos like Reels and TikTok rapidly trigger dopamine, stress, and attention circuits—discover how they impact your brain, mood, and focus, plus practical tips to restore balance.
    By Mohamad-Ali Salloum, PharmD April 17, 2026
    How short‑form videos rapidly flip your emotions, affect attention, sleep, and motivation—and what science says about protecting your mental health.
    By Mohamad-Ali Salloum, PharmD April 17, 2026
    Discover the science behind resisting temptation—how willpower works, what drains it, and how lifestyle factors like fatigue, stress, and habits influence self‑control.
    By Mohamad-Ali Salloum, PharmD April 15, 2026
    How science, psychology, and society intersect — and what it means for the future of addiction prevention and recovery
    By Mohamad-Ali Salloum, PharmD April 13, 2026
    How emerging neuroscience, biomarkers, technology, and personalized medicine are reshaping the next decade of addiction research.
    More Posts